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Planar bone scans play an important role in the staging and monitoring of malignancy and 
metastases. Metastases in the lumbar spine are associated with significant morbidity, therefore 
accurate diagnosis is essential. Supplementary imaging after planar bone scans is often, required to 
characterise lesions, however, this is associated with additional radiation dose. This paper provides 
information on the comparative effective dose and effective risk from supplementary lumbar spine 
radiographs, low-dose CT (LDCT) and diagnostic CT (DCT). 
Method 
Organ dose was measured in a phantom using thermo-luminescent dosimeters. Effective dose and 
effective risk were calculated for radiographs, LDCT, and DCT imaging of the lumbar spine.  
Results 
Radiation dose was 0.56mSv for the antero-posterior and lateral lumbar spine radiographs, 0.80mSv 
for LDCT, and 3.78mSv for DCT. Additional imaging resulted in an increase in effective dose of 
12.28%, 17.54% and 82.89%for radiographs, LDCT and DCT respectively. Risk of cancer induction 
decreased as age increased. The difference in risk between the modalities also decreased. Males had 
a statistically significant higher risk than female patients (p=0.023) attributed to the sensitive organs 
being closer to  the exposed area. 
Conclusion 
Effective Dose for LDCT is comparable to radiographs of the lumbar spine. Due to the known benefits 
image fusion brings it is recommended that LDCT replace radiographs imaging for characterisation of 
lumbar spine lesions identified on planar bone scan. DCT is associated with significantly higher 
effective dose than LDCT. Effective risk is also higher and the difference is more marked in younger 
female patients.  
  
Introduction 
Planar whole-body bone scintigraphy (BS) using Technetium 99m phosphates or phosphonates [1] 
and a gamma camera continues to play an important role in the staging and monitoring of malignant 
disease due to its ability to demonstrate lesions earlier than conventional radiographic methods [1, 
2]. The lumbar spine is a common site for bony metastases arising from primary tumour sites in the 
prostate and breast due to venous drainage into the vertebral plexus [3]. Metastases in the spine are 
associated with significant morbidity, therefore accurate and early diagnosis is important for 
effective patient management [3-5]. Multiple lesions in the spine detected using BS does not provide 
a definitive diagnosis but are suggestive of metastatic disease [6]. When solitary spinal lesions are 
discovered a definitive diagnosis is challenging due to the spectrum of potential pathological 
processes. These cases are often referred for additional imaging to localise and/or characterise 
them.  
Over a decade ago research lead to a significant change in scanning technique [1]. BS evolved to 
include single photon emission computed tomography (SPECT) and later computed tomography (CT), 
with SPECT-CT now regarded as an essential tool in diagnosing and assessing metastatic bone 
disease [7].  Prior to tomographic imaging, patients were referred for supplementary imaging to help 
localise or characterise a lesion: typically using conventional plain radiography, CT or MRI. Hybrid 
imaging systems now allow fusion of CT and SPECT images, providing the clinician with physiological 
data overlaid on anatomical information. This removes the necessity for side-by-side comparison.  
The benefits of image fusion in nuclear medicine imaging are covered extensively in literature, which 
reports an increase in the accuracy, sensitivity, specificity and diagnostic confidence [8-11].  These 
benefits are associated with additional risk, since supplementary imaging requires additional 
radiation dose to the patient. Research has shown that the additional dose from CT acquisitions 
acquired as part of a SPECT-CT study are not insignificant and on occasions can exceed the dose from 
the administration of the radiopharmaceutical. Increases in effective dose of between 2% and 600% 
are reported [12].  
The early use of CT in combination with SPECT was aimed at attenuation correction (AC) and 
consisted of a CT component with fixed acquisition parameters. These scanner types are frequently 
referred to as low-dose with an effective dose 80-85% lower than diagnostic quality CT scans [12-
15]. Diagnostic CT (DCT) can be used to aid diagnosis rather than correcting the emission data alone 
[16] and also provide localisation data [17]. Regardless of the modality the additional dose has to be 
taken into account in the justification of the exposure [18, 19]. Justification should ensure that the 
benefit of the exposure outweighs the potential risk from the additional exposure.  
The additional dose from the CT component of SPECT-CT has been investigated [12-15]. Larkin et al 
[14], Sharma et al [12] and Montes et al [15] use the dose length product and conversion (k) factors 
to calculate effective dose. Hara et al [13] measured organ dose with thermoluminescent dosimeters 
(TLD) however only organs within the primary beam were measured. The paper does not recreate 
the clinical situation where organs outside the primary beam would be subject to scatter radiation.  
The aims of our research are to calculate effective dose and effective risk from imaging of the 
lumbar spine using radiographs, LDCT and DCT. From this data the additional dose over BS alone are 
calculated. Male and female effective risk will be compared to figures from SPECT alone and SPECT 
plus supplementary imaging.  
Method 
Using an adult dosimetry phantom (ATOM 701D (CIRS Inc, Virginia USA)), organ dose was measured 
using thermo-luminescent dosimeters (TLD100H (Thermo Fisher Scientific Massachusetts, USA)) . 
Effective dose and effective risk were calculated as described below. Three imaging systems were 
used in this study. The first was radiographs using a Wolverson Acroma General X-ray system 
(Willenhall, UK) with an Agfa computed radiography system (Agfa Health Care, Mortsel, Belgium). 
The second was multi-detector diagnostic CT (DCT) (Toshiba Aquillion 16, Toshiba Medical Systems 
Corporation, Tochigi-ken, Japan). The third was a low-specification CT component from a hybrid 
SPECT-CT system (low-dose CT (LDCT)) (GE Infinia Hawkeye 4, GE Healthcare, Little Chalfont, UK). 
Imaging equipment quality control for tube output and automatic exposure devices met the 
required standards and manufacturer guidelines [20-22]. Air-calibrations for the two CT systems 
were performed as part of the warm-up procedures. The imaging parameters were based on those 
used in the clinical environment and had undergone an optimisation process through audits of 
image quality and diagnostic reference levels. The automatic exposure control for radiographs and 
the mA modulation function for the DCT were used. For LDCT exposure factors for an average sized 
patient were used (Table 2). 
The Phantom 
The anthropomorphic dosimetry phantom consists of 39 contiguous sections of differing density 
epoxy resin (representing bone, lung and soft tissue) that when put together make up the head and 
torso of an adult male. TLD locations were positioned for precise dosimetry of specific internal 
organs. Whole body effective dose calculation was completed  using the ATOM 701-D configuration 
that utilises a total of 271 TLDs over 22 organs [23, 24].  
For AP and lateral lumbar spine, the area of interest adhered to criteria set out in a standard 
radiography technique book [25]. The medial-sagittal and medial-coronal planes, the field of view 
and the centre for antero-posterior and left lateral projections of the lumbar spine were marked 
onto the phantom’s surface with permanent marker pen and radiolucent markers were used to aid 
positioning of the CT acquisitions (Figure 1). 
 
Figure 1 marking the phantom for AP and left lateral lumbar spine projections and CT lumbar spine. 






Positioning the phantom for the LDCT acquisition on the SPECT-CT hybrid system involved the use of 
external positioning aids. Commercially available laser spirit levels allowed the phantom to be 
centrally positioned on the table and parallel to its long axis. A scout view is not routinely acquired 
as planning of the CT range is performed on patients using the emission data. To ensure close 
replication of clinical practice the scan range was determined by setting a zero refresh rate on the 
positioning monitor and placing a 57Co source on the markings on the phantom until it was visible on 
the scanner’s positioning monitor. These two points corresponded to the upper and lower limit of 
the CT acquisition. To ensure the use of the unsealed source in this manner did not contribute to the 
dose recorded by the TLDs, the dose recorded in 5 seconds at a distance of 1 cm in air was 
calculated. Using the reference activity of 3.7 MBq for the Cobalt source resulted in 6.53 x 10-4 mGy. 
This value is below the sensitivity of the TLDs and so was considered negligible when calculating the 
dose from the TLDs in the phantom.  
 
Thermoluminescent dosimeters 
The TLDs were read using a Harshaw 3500 manual TLD reader one day after their exposure. To 
ensure accuracy and reproducibility the TLDs were subjected to quality control checks. The TLDs 
were annealed by heating to 240oC for 10 minutes. They were then exposed to a uniform field of X-
radiation using a general x-ray unit, processed and grouped together into batches of similar 
response. To ensure repeatability the batches were annealed and exposed to the same uniform field 
and their responses compared. A paired student t-test was performed and there was no significant 
difference in the responses of the two exposures (p>0.1). The inter batch coefficient of variance was 
calculated and was less than 2.0%. Calibration was performed on each batch using a general x-ray 
unit at energies of 120kV and 80kV to correspond with settings used in the imaging protocols [26]   
The TLDs were positioned in the phantom at locations of the organs identified in ICRP 103 (Table 1) 
at the organ positions specified by the manufacturer [23, 24, 27]. Five TLDs remained with the 
phantom at all times apart from during image acquisition for background correction. 
Table 1 Number of TLDs used in critical organs 
Organ Number of TLD Organ Number of TLD 
Adrenals 2 Liver 30 
Bladder 16 Lungs 36 
Brain 11 Oesophagus 3 




Clavicle 20,  
Cranium 4 







Thoraco-lumbar Spine 9 
Eyes* 2 Spleen 14 
Gall Bladder 5 Stomach 11 





Small intestine 5 
Thyroid 10 
Kidneys 16 Thymus 4 
* Not included in effective dose calculations 
 TLDs located in the anterior of C2 and upper oesophagus were used to calculate extra thoracic 
organ dose 
 TLDs located in the left and right lingula of the mandible and to the left and right of the sublingual 
fossa were used to calculate salivary gland organ dose 
× TLDs located in the left and right lingula of the mandible were used to calculate oral mucosa organ 
dose 
 
To increase the signal to noise ratio of the TLD readings three complete exposures were performed 
using the acquisition parameters shown in Table 2. This resulted in a cumulative dose being recorded 
on the TLDs which was divided by three to give a dose per exposure. Effective dose for the three 
modalities was calculated using tissue weighting factors listed in ICRP report 103 [27] (see Table 3). 
Statistical analysis was performed using two-way ANOVA with post hoc testing with Bonferroni 
correction.  
  
Table 2 Parameters used for imaging the lumbar spine in CR, diagnostic CT and Low Dose CT 
Radiographs 
 kV AED chamber Post mAs 
AP 75 Central Mean 60 (SD=0) 
Left lateral 80 Central Mean 72 (SD=0) 
 
Diagnostic CT 
Scan Projection Radiograph 
 kV mAs Scan range 
AP 120 150 250 mm 
Left Lateral 120 45 250 mm 
 
Axial scan 









SD:        7.5 
0.75 0.938 16 mm  
16x1 mm 
245 mm 
Upper- Mid T12 
Lower- 
 Upper S3 
 
Low Dose CT 























4 x 5 mm 
 
245 mm 
Upper- Mid T12 
Lower- Upper S3 
 
 
Table 3 Tissue weighting factors from ICRP report 103 [18] 
Tissue WT ∑wT 
Bone Marrow, Colon, Lung, Stomach, Breast, Remainder tissues* 0.12 0.72 
Gonads 0.08 0.08 
Bladder, Oesophagus, Liver, Thyroid 0.04 0.16 
Bone Surface×, Brain, Salivary glands, Skin× 0.01 0.04 
*adrenals, extrathoracic region, gallbladder, heart, kidneys, lymphatic nodes× ,oral mucosa, pancreas, 
prostate, small intestine, spleen, thymus 
×excluded in this study. 
 
Risk calculations were carried out following a method described by Brenner [28, 29]. Lifetime risk of 
cancer incidence figures were obtained from Wall et al [30]. The sum of the product of the measured 
organ dose (mGy) and the life time risk of cancer incidence for that organ (percentage per mGy) 
gave the effective risk. Resources dictated that the phantom used within this study was male, 
however by using TLD readings from locations that correspond with the gonads and uterus and 
excluding the male testes and prostate it was possible to calculate an effective risk for females.  
Organ and effective dose from the administration of 800 MBq 99mTc labelled phosphate or 
phosphonates was calculated using dose per unit activity (mSv/MBq) from Bombardieri et al [1]. 




A comparison of dose data as displayed by the modalities is shown in Table 4. DLP and CTDi are 
significantly higher for DCT compared to LDCT. This supports the findings of the dosimetry data that 
DCT will result in a higher dose. Comparison of the effective dose from the three supplementary 
imaging techniques is shown in Figure 2. Imaging using DCT results in a higher effective dose 
compared to radiographs and LDCT. The error bar for DCT is larger due to the 2% error in the TLDs 
being applied to a larger dose reading.    
 
Table 4 Comparison of DAP/DLP and CTDi 
 Radiographs LDCT DCT 
DAP (mGy.cm2) 2873 -- -- 
DLP (mGy.cm) -- 96.0 349.6 
CTDi (mGy) -- 3.97 20.0 
 
Figure 2 Effective dose from the supplementary imaging modalities 
 
Effective dose is calculated from the sum of the weighted organ doses and does not indicate the 
difference to individual organs. Table 5 and  
Table 6 illustrate the organ dose from and increase due to the supplementary imaging modality 
compared to the calculated organ dose from the administration of the radiopharmaceutical. Certain 
organs, for example the colon, liver and stomach, exhibit a large increase due to the low uptake of 
radiopharmaceutical but are situated within the scan range. There is a consistent difference in organ 
dose between DCT and LDCT and DCT and radiographs showing the distribution of the organ dose is 





























Effective dose from 
supplementary imaging modality 
  
Table 5 comparison of organ dose from the three supplementary modalities compared to the Bone scan (800MBq 
phosphate or phosphonate). 
  Absorbed dose (mGy) 
Organ BS Radiographs LDCT DCT 
Active bone marrow 7.36 0.15 0.33 1.75 
Bladder 38.40 0.55 0.59 3.83 
Brain 1.36 0.00 0.00 0.01 
Breast 0.57 0.04 0.07 0.44 
Colon 2.16 1.58 2.12 9.00 
Liver 0.96 1.42 1.42 7.23 
Lungs 1.04 0.11 0.15 1.16 
Oesophagus 0.80 0.06 0.11 0.72 
Stomach 0.96 1.29 2.14 9.86 
Thyroid 1.04 0.01 0.02 0.09 





Table 6 Increase in organ dose for the organs 
 
Absorbed dose (mGy) 
Organ BS only 
BS & Radiographs  BS & LDCT  BS & DCT  
mGy % increase mGy % increase mGy % increase 
Active bone 
marrow 7.36 7.51 2.09 7.69 4.49 9.11 23.76 
Bladder 38.40 38.95 1.43 38.99 1.55 42.23 9.97 
Brain 1.36 1.36 0.04 1.36 0.02 1.37 0.73 
Breast 0.57 0.61 7.72 0.64 12.39 1.01 77.86 
Colon 2.16 3.74 73.26 4.28 98.2 11.16 16.54 
Liver 0.96 2.38 147.58 2.38 147.73 8.19 753.27 
Lungs 1.04 1.15 10.14 1.19 14.83 2.20 111.76 
Oesophagus 0.80 0.86 7.87 0.91 13.93 1.52 89.4 
Stomach 0.96 2.25 134.74 3.10 222.95 10.82 1027.35 
Thyroid 1.04 1.05 0.83 1.06 2.23 1.13 8.81 
Remainder 1.52 2.31 52.04 2.62 72.41 6.73 342.47 
 
Using data published by Wall et al[30], life time cancer risk for all cancers and cancers of the organs 
identified in  
Table 6 were calculated. Comparison of risk between bone scan (BS) only, BS with conventional 
radiography, BS with low dose CT, and BS with diagnostic CT from 40 to 89 years are shown in Figure 
3,  
Figure 4 and Figure 5. 









































Age at exposure (years) 
Female Bone scan plus Diagnostic CT
Male Bone scan plus Diagnostic CT
Female Bone scan plus "Low Dose" CT
Male Bone scan plus "Low Dose" CT
Female Bone scan plus x-ray
Male Bone scan plus x-ray
Female Bone Scan Only
Male Bone Scan Only
 
Figure 4 Effective risk from exposure for all cancers for a female Euro-American population 
 
























Age at exposure (years) 
Female Bone scan plus Diagnostic CT
Female Bone scan plus "Low Dose" CT
Female Bone scan plus x-ray























Age at exposure (years) 
Male Bone scan plus Diagnostic CT
Male Bone scan plus "Low Dose" CT
Male Bone scan plus x-ray
Male Bone Scan Only
 
Discussion 
Image fusion has been shown to increase accuracy and reporter confidence [8-11]. It has been 
suggested that DCT that can further aid diagnostic decisions due to its ability to acquire and display 
submillimetre structures thus showing the accurate location and internal architecture of a lesion [31-
35]. To date little data directly comparing the additional organ and effective dose and effective risk 
for all available supplementary imaging options has been published. Our results show that the 
effective dose from lumbar spine imaging using radiographs was 0.56 mSv (±0.09), LDCT 0.80 mSv 
(±0.12) and DCT was 3.78 mSv (±0.56), The calculated effective dose from the administration of 800 
MBq of 99mTc labelled phosphate or phosphonate is 4.56 mSv. Thus the additional effective dose 
from supplementary imaging is 12.3% for radiographs, 17.5% for LDCT and 82.9% for DCT. 
This increase in effective dose was hypothesised and this result is in agreement with other research 
[12-14, 36]. However consideration of effective dose does not provide the narrative as it is not 
apparent which organs contribute to this increase.  
Table 6 shows there are increases in organ dose from the supplementary imaging techniques. 
Comparison of organ doses using two way ANOVA showed that there was a statistically significant 
difference between the three options (p=0.001). Post hoc testing with Bonferroni correction showed 
that there was a statistically significant difference between BS & DCT and BS & LDCT (p=0.001) and 
BS & DCT and BS & radiographs (p=0.001).  There was no statistical difference between BS & LDCT 
and BS & radiographs (p=0.810). On this basis there is a strong rationale for the use of LDCT over 
radiographs for imaging the lumbar spine. There is no statistically significant increase in organ dose 
and literature suggests that accuracy and clinician confidence is increased when using LDCT 
compared with radiographs.  
There is no change to the urinary bladder dose and there is a relatively small increase in dose (from 
38.4 mGy to 42.23 mGy (9.91%) for BS & DCT, 38.99 (1.55%) for LDCT and 38.95 mGy (1.43%) for BS 
& radiographs). The stomach receives one of the lowest doses from the radiopharmaceutical (0.96 
mGy). Following supplementary imaging this figure increases to 10.82 mGy (+1027.35%) for BS+DCT, 
3.10 mGy (+222.95%) for BS & LDCT and 2.25 mGy (+134.74%) for BS & radiographs. These results 
are due to the organ being directly in the field of view when imaging the lumbar spine. While these 
results are specific to lumbar spine imaging they have shown that the supplementary imaging can 
significantly increase organ dose.  
Effective dose is commonly used in medical imaging to compare the risks from different modalities 
or techniques.  Effective dose should not be used to calculate risk to an individual patient or patient 
types as it does not consider the age of the patient. Effective risk is a method described by Brenner  
[28, 29, 37] and Wall [30] in which tissue weighting factors are replaced with organ-specific 
radiation-induced cancer risk , such as those published by The Nuclear and Radiation Studies board 
[38], and Wall [30]. Discussion about the use of effective dose and effective risk are beyond the 
remit of this article but are reported widely in literature [28-30, 37, 39-42].  
 
Figure 4 and Figure 5 illustrate the difference in the lifetime risk of radiation induced cancer 
between the supplementary modalities with increasing age. The difference between these values 
does decrease with age and when comparison is made between the effective risk for patients over 
70 the difference is very small. The higher organ doses for BS & DCT is reflected in the higher risks 
for these ages with an incidence of 217 per million exposures for females and 154 per million 
examinations for males.  
A limitation of this study is that the whole of the lumbar spine was imaged by the three modalities. 
In clinical practice a localised CT scan based on the planar and SPECT bone scan could be performed 
as opposed to the whole lumbar spine. This would limit the exposure to the area of interest meaning 
that organ doses would be less.  This is likely not to be the case for radiographs where the full 
lumbar spine would be imaged. In other words, LDCT would likely be lower than radiographs. 
This study uses the standard adult male phantom for dosimetry measurements. External validity of 
the research could be improved with the use of a female anthropomorphic phantom. However initial 
comparison of risk between male and female shows that the figures for male patients are higher. 
The reason for the difference is due differences in the sensitivities of the tissues. Sensitive organs in 
the female patient such as the breast tissue receive very little additional dose in imaging the lumbar 
spine as these are outside the field of view. Also, the specific focus of this work is the lumbar spine; a 
lesion requiring further clarification in the thoracic spine would result in breast tissue receiving a 
higher dose and would affect effect risk. Further research into supplementary imaging of other 
common sites of bony pathology is therefore warranted.  
In older patients there is little additional risk however, in younger patients, risk is greater. In patients 
over 70 the difference in risk from the additional imaging decreases to the point where performing a 
DCT instead of LDCT could be justified. DCT can provide diagnostic image quality and afford good 
diagnostic value in the characterisation of a lesion.   
Even-Sapir et al [31] suggest that referral for and justification of DCT over LDCT should be taken on a 
case-by-case basis and the benefits of the higher image quality and therefore high dose balanced 
against the risks [31]. There are likely to be instances when higher resolution images are required 
and in these cases the higher dose and associated risk from DCT is justified. The diagnostic value of 
the supplementary imaging options is beyond this work but research has shown the benefit of 
supplementing SPECT with CT [8, 31, 43, 44]. Further research in the usefulness of higher 
dose/higher quality CT acquisitions compared to low dose would facilitate the risk/benefit 
discussion. 
Accepted practice is to use CT as a supplementary imaging modality over radiographs due to the 
benefits image fusion brings [45-47]. Recent papers consider the use of 16 slice or higher CT 
scanners and they note that the improved image quality allows reporters to comment upon the 
internal structure of a lesion as well as identifying its location [8, 9, 31, 43, 44, 48]. The current work 
has shown acquisitions using DCT result in a statistically significant higher dose. 
 
Conclusion 
Our work demonstrates that a DCT acquisition result in an effective dose and effective risk that is 
significantly higher than a LDCT acquisition.  The LDCT system used in our work has demonstrated a 
small increase in dose and risk compared with radiographs. However LDCT brings the benefits of 
improved diagnostic confidence and thus are recommended as the preferred choice of bone scan 
supplemental imaging for bony metastases.  
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